Last updated: April 26, 2026
Otsuka v. Apotex (1:15-cv-00109): Litigation Summary and Patent-Exposure Analysis
Otsuka Pharmaceutical Co. Ltd. v. Apotex Inc. (D. Del.; C.A. No. 1:15-cv-00109) is a U.S. Hatch-Waxman patent litigation brought by Otsuka against Apotex. The case centers on Apotex’s challenge to Otsuka’s asserted U.S. patents in the context of a generic product launch. Public case records identify the docket and parties, but they do not provide in-line, patent-specific merits outcomes (e.g., asserted patent numbers, claim constructions, verdicts, or final judgment) in the material available through the case docket header alone. As a result, the analysis below focuses on what the litigation posture supports with high confidence and what is not established by the accessible record.
What is the case and what posture does it reflect?
Case metadata
- Court: U.S. District Court for the District of Delaware
- Case number: 1:15-cv-00109
- Parties: Otsuka Pharmaceutical Co. Ltd. (plaintiff) vs. Apotex Inc. (defendant)
- Nature: Patent litigation under the Hatch-Waxman framework (ANDA-related)
What the public docket identifies (high confidence)
- The dispute is between the NDA holder/patent owner (Otsuka) and a generic applicant or ANDA affiliate (Apotex).
- The docket reflects a formal infringement validity/unenforceability/non-infringement contest in federal court, typical of ANDA Paragraph IV filings.
What the public docket excerpt does not establish (and therefore cannot be asserted here)
- Which specific U.S. patents Otsuka asserted.
- Whether the case resolved via trial, stipulated judgment, summary judgment, or settlement.
- Any claim-level outcomes (construction, infringement findings) and any damages determinations.
- Launch timing, design-around commitments, or agreed injunction scope.
Which patents were at issue?
No asserted patent numbers appear in the available case docket header material referenced for 1:15-cv-00109. Without patent identifiers in the accessible record, it is not possible to provide a reliable claim-by-claim or patent-by-patent litigation analysis (e.g., “’xxx patent: valid but not infringed due to element X not met”).
What claims and defenses typically drive this docket class?
While the docket header does not provide the asserted claims or defenses, U.S. ANDA patent cases in the District of Delaware commonly turn on the following elements of proof:
- Infringement
- Claim charts mapping each asserted claim element to the accused ANDA product attributes (active ingredient, formulation characteristics, dosing regimen, and any claimed structural limitations).
- Validity
- Obviousness (35 U.S.C. §103), anticipation (35 U.S.C. §102), lack of enablement/indefiniteness, or subject-matter eligibility under the applicable framework.
- Non-infringement and design-around
- Whether the generic product avoids one or more claim limitations, including formulation or process limitations.
- Enforcement barriers
- Inequitable conduct, prosecution history estoppel, or other doctrines (case-specific).
This framework matters commercially because it drives whether a generic applicant can launch “at risk” or must wait for patent expiry or a non-infringement/invalidity outcome.
What does the case suggest about Otsuka’s patent positioning?
Given the plaintiff’s decision to sue and maintain a Delaware docket, the business inference supported by the litigation existence is limited to:
- Otsuka identified one or more patents it believed were enforceable against Apotex’s intended generic activity.
- Otsuka sought relief strong enough to keep the generic off-market or delay launch pending adjudication or resolution.
What cannot be supported from the accessible docket header alone is:
- Whether Otsuka’s patents were later found invalid, not infringed, or enjoined.
- Whether the asserted patents had independent drug substance coverage, formulation coverage, or method-of-use coverage.
- Whether the case involved a portfolio strategy (multiple patents with staggered expiration).
Timeline and docket landmarks (what can be stated from accessible record)
The accessible information for 1:15-cv-00109 in this prompt context does not include specific docket events such as:
- complaint filing date,
- answer date,
- motions schedule (Rule 12, summary judgment),
- Markman/claim construction hearing date,
- trial date or dispositive orders,
- final judgment date.
Accordingly, no date-based chronology is provided beyond the case’s existence and identification.
Commercial exposure analysis: how investors and R&D teams typically map this docket
Even without the patent numbers and final outcomes, a business team can map exposure by case “class”:
- If final judgment favors Otsuka: Apotex’s generic launch is delayed until patent expiry or a redesign, and Otsuka’s exclusivity is extended through enforceable rights.
- If final judgment favors Apotex: Otsuka faces earlier generic erosion of sales; the remaining relevant patents (if any) determine whether exclusivity survives.
- If settlement resolves: the key commercial parameter becomes the effective “entry date” created by any agreed non-launch period, licensing terms, or carve-outs.
For a high-stakes R&D or investment decision, the crucial missing variables in the accessible record are:
- asserted patent list,
- claim construction impacts,
- final disposition (trial verdict, dispositive order, settlement).
Comparative impact: what this case likely means versus other Otsuka v. generic patterns
In Otsuka’s broader ANDA litigation footprint, plaintiffs commonly assert:
- drug composition and crystalline form patents,
- formulation or dosing regimen patents,
- secondary patents tied to stability, process, or patient-usage parameters.
But the prompt’s provided record does not tie 1:15-cv-00109 to any specific Otsuka product or technology. Without that linkage, the comparison risks becoming speculation, which is not included.
Litigation risk matrix (based only on what the docket proves)
The existence of 1:15-cv-00109 proves only this:
- Otsuka believed it had enforceable intellectual property barriers against Apotex’s planned generic.
From there, the risk matrix can be framed at the program level without claim-specific detail:
| Decision area |
What this case proves |
What it does not prove |
| IP enforceability |
Otsuka asserted patents and sued Apotex in Delaware |
Which patents, how strong on validity/infringement |
| Launch timing |
Litigation creates leverage to delay generic entry |
Actual entry date, injunction scope, settlement terms |
| R&D strategy |
Generic pathway was challenged in federal court |
Whether Otsuka’s claims were narrow or broad, and what design-arounds succeeded |
| Investment diligence |
A Delaware ANDA docket exists between these parties |
Case outcome and remaining patent estate relevance |
Key takeaways for business action
- The litigation exists and is formally identified as Otsuka v. Apotex, D. Del., 1:15-cv-00109, indicating Hatch-Waxman patent enforcement activity.
- The accessible record does not provide the asserted patent numbers or merits outcome, so patent-level commercial impact (entry timing, injunction, invalidity) cannot be quantified from the provided docket header information alone.
- For any investment or competitive R&D decision tied to this specific case, the immediate due diligence target is the docket’s dispositive entries and the complaint’s asserted patent list, since those two items determine exclusivity effect and design-around feasibility.
Key Takeaways
- Otsuka Pharmaceutical Co. Ltd. v. Apotex Inc. is a Hatch-Waxman-style patent case in the District of Delaware under case number 1:15-cv-00109.
- The litigation record identifies the parties and case identity, but does not provide in the available material the asserted patents, claim issues, or final outcome, preventing patent-specific conclusions.
- Any business decision tied to this docket must hinge on (1) the asserted patent list and (2) the final disposition; those are not established by the accessible reference in this prompt.
FAQs
-
What court handled Otsuka v. Apotex (1:15-cv-00109)?
The case was filed in the U.S. District Court for the District of Delaware.
-
Is this an ANDA-related patent case?
The case fits Hatch-Waxman patent litigation between an innovator (Otsuka) and a generic company (Apotex).
-
What is the key business value of knowing the asserted patents?
Asserted patent numbers determine whether the generic’s design-around targets product attributes that can be engineered and whether exclusivity remains enforceable.
-
Can the litigation outcome be concluded from the case header alone?
No. The accessible reference in this prompt does not state merits rulings, settlement terms, or final judgment.
-
Where do investors usually focus for launch timing from these dockets?
The docket entries tied to dispositive orders or settlement/judgment and the effective date of any entry restriction.
References (APA)
- U.S. District Court, District of Delaware. Otsuka Pharmaceutical Co. Ltd. v. Apotex Inc., Civil Action No. 1:15-cv-00109.
